ArQule Announces Initiation Of Clinical Programs With ARQ 197 In Germ Cell Tumors And Colorectal Cancer
WWW.MEDICALNEWSTODAY.COM - ArQule, Inc. (Nasdaq: ARQL) announced the initiation of a Phase 2, single agent trial with ARQ 197 in germ cell tumors (GCT), including testicular and non-central nervous system (non-CNS) tumors, and a Phase 1/2 clinical trial designed to evaluate the safety of ARQ 197 administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer (CRC) who possess the…
First tweeted by healthytweet.
From the Front Page
- Comments
- Tweets (14)
Tweets
Sorry there have been no tweets in the last 7 days.
